Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8668911
Streptococcus vaccine compositions and methods of using the same
granted -
US 8669258
Treatment for gastroparesis using sepiapterin
granted -
US 8668863
Dendritic macroporous hydrogels prepared by crystal templating
granted -
US 8663624
Adeno-associated virus virions with variant capsid and methods of use thereof
granted -
US 8664212
Diazo bicyclic Smac mimetics and the uses thereof
granted -
US 8664251
Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
granted -
US 8663950
Production of a monoclonal antibody therapeutic against west nile virus in plants
granted -
US 8664177
Peptide compositions and methods for treating patients
granted -
US 8663649
Diagnosis and treatment of Trypanosoma cruzi infection and Chagas disease
granted -
US 8663635
N-cadherin: target for cancer diagnosis and therapy
granted -
US 8663602
Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
granted -
US 8658168
Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells
granted -
US 8658603
Compositions and methods for inducing an immune response
granted -
US 8658626
Controlled release corticosteroid compositions and methods for the treatment of otic disorders
granted -
US 8658664
Cyclopamine tartrate salt and uses thereof
granted -
US 8658778
hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
granted -
US 8658627
Pregnancy hormone combination for treatment of autoimmune diseases
granted -
US 8658622
Methods and compositions for preventing and treating a disease related to glycan dysregulation
granted -
US 8652467
Dek protein compositions and methods of using the same
granted -
US 8653283
Anticancer agents
granted -
US 8653243
Pertussis antibodies and uses thereof
granted -
US 8653034
Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives
granted -
US 8653057
Prophylactic perioperative testosterone supplementation for protection of and recovery of function
granted -
US 8652503
Bone paste
granted -
US 8652475
Inhibition of factor B, the alternative complement pathway and methods related thereto
granted -
US 8652366
Aerosol-mediated particle synthesis
granted -
US 8653027
Method of treatment of type-1 diabetes with humanin analogues
granted -
US 8648119
Controlled release immunomodulator compositions and methods for the treatment of otic disorders
granted -
US 8648059
Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
granted -
US 8648105
Diarylthiohydantoin compounds
granted -
US 8648112
Therapeutic uses of urolithins
granted -
US 8648102
Compounds for treatment of cell proliferative diseases
granted -
US 8647670
Biocompatible rapid-gelating hydrogel and associated preparation method of spray
granted -
US 8647637
Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
granted -
US 8642534
Proteins and polynucleotides of Vibrio cholerae
granted -
US 8642788
Activators of executioner procaspases 3, 6 and 7
granted -
US 8642738
Modified vitamin K-dependent polypeptides
granted -
US 8642656
Calixarene-based peptide conformation mimetics, methods of use, and methods of making
granted -
US 8642604
Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
granted -
US 8642561
Peptides whose uptake by cells is controllable
granted -
US 8642614
Toll-like receptor modulators and uses thereof
granted -
US 8642282
Inhibitors of nitric oxide synthase for treatment of melanoma
granted -
US 8642550
Chimeric natriuretic peptides without hypotensive inducing capability
granted -
US 8637675
Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
granted -
US 8637009
Thermostabilization of proteins
granted -
US 8637503
Phenothiazine enantiomers as agents for the prevention of bone loss
granted -
US 8637565
Salinosporamides and methods for use thereof
granted -
US 8637470
Small humanin-like peptides
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory